Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Common Equity (2016 - 2025)

Historic Common Equity for Organogenesis Holdings (ORGO) over the last 10 years, with Q3 2025 value amounting to $255.1 million.

  • Organogenesis Holdings' Common Equity fell 840.76% to $255.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.1 million, marking a year-over-year decrease of 840.76%. This contributed to the annual value of $262.9 million for FY2024, which is 565.77% down from last year.
  • Latest data reveals that Organogenesis Holdings reported Common Equity of $255.1 million as of Q3 2025, which was down 840.76% from $233.2 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Common Equity registered a high of $278.7 million during Q4 2023, and its lowest value of $157.3 million during Q1 2021.
  • Over the past 5 years, Organogenesis Holdings' median Common Equity value was $256.3 million (recorded in 2022), while the average stood at $246.8 million.
  • As far as peak fluctuations go, Organogenesis Holdings' Common Equity soared by 40048.11% in 2021, and later crashed by 1263.46% in 2025.
  • Organogenesis Holdings' Common Equity (Quarter) stood at $241.3 million in 2021, then rose by 10.08% to $265.7 million in 2022, then grew by 4.89% to $278.7 million in 2023, then decreased by 5.66% to $262.9 million in 2024, then fell by 2.96% to $255.1 million in 2025.
  • Its Common Equity was $255.1 million in Q3 2025, compared to $233.2 million in Q2 2025 and $242.9 million in Q1 2025.